Vaxigrip (Seasonal Influenza Vaccines) Forecast and Market Analysis
GlobalData has released its new PharmaPoint Drug Evaluation report, “Vaxigrip (Seasonal Influenza Vaccines) Forecast and Market Analysis”. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as Sanofi’s Fluzone and Vaxigrip, GlaxoSmithKline’s Fluarix and FluLaval and Novartis’ Fluvirin garner the majority stake of the market. However, with the entrance of vaccines with novel routes of administration, such as AstraZeneca’s intranasal FluMist and Sanofi’s Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the adoption of such vaccines over the traditional intramuscular vaccines. GlobalData also anticipates that manufacturers that launch quadrivalent formulations will steal market share, patient share, and revenue from the trivalent influenza vaccines currently available.
Vaxigrip is a trivalent, inactivated vaccine designed for immunization against seasonal influenza viruses. The vaccine is designed for administration via intramuscular injection, where the viral antigens elicit an immune response, which helps protect the recipient against influenza infection. Vaxigrip is marketed by Sanofi as Gripavac in Spain and Inactivated Influenza Vaccine (Split Virion) BP in the UK. Mutagrip is another trivalent, inactivated influenza vaccine marketed by Sanofi, that is almost identical in formulation and dosing to Vaxigrip.
Overview of seasonal influenza, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on Vaxigrip including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for Vaxigrip for the top six countries from 2012 to 2022.
Sales information covered for France, Germany, the UK, Italy, India and China.
Reasons to buy
Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for seasonal influenza
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of Vaxigrip performance
Obtain sales forecast for Vaxigrip from 2012 to 2022 in France, Germany, the UK, Italy, India and China.